Enoxaparin: Difference between revisions
(Redirected page to Low Molecular Weight Heparin) |
|||
(14 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==General== | |||
*Type: [[Low molecular weight heparin]] | |||
*Dosage Forms: subcutaneous | |||
*Common Trade Names: Lovenox | |||
[[Category: | ==Adult Dosing== | ||
===<u>Therapeutic</u> anticoagulation (e.g. treating [[DVT]]/[[PE]], [[unstable angina]])=== | |||
*1mg/kg SC q12h | |||
{{Chemical prophylaxis of VTE}} | |||
==Pediatric Dosing== | |||
''Off-label'' | |||
*DVT prophylaxis: | |||
**<2 months: 0.75 mg/kg SC q12hr | |||
**≥2 months: 0.5 mg/kg SC q12h | |||
*Therapeutic anticoagulation: | |||
**<2 months: 1.5 mg/kg SC q12hr | |||
**≥2 months: 1 mg/kg SC q12hr | |||
==Special Populations== | |||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | |||
*Lactation: Unknown risk | |||
*Renal Dosing | |||
**Renal impairment (creatinine clearance <30) | |||
***Use 50% of usual dose or use UFH instead | |||
*Hepatic Dosing: not established | |||
*Obesity | |||
**Weight-based dosing safe up to 190kg (no data available thereafter) | |||
==Indications== | |||
*[[DVT]] | |||
*[[PE]] | |||
*[[NSTEMI]] | |||
*[[STEMI]] | |||
==Contraindications== | |||
*Allergy to class/drug | |||
==Adverse Reactions== | |||
*Bleeding | |||
*Pruritus | |||
*Local skin reaction | |||
==Pharmacology== | |||
*Half-life: 4.5h | |||
*Metabolism: hepatic | |||
*Excretion: urine | |||
*Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III | |||
==See Also== | |||
*[[Heparin (Unfractionated)]] | |||
*[[Coagulopathy (Main)]] | |||
*[[Anticoagulant reversal for life-threatening bleeds]] | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] |
Latest revision as of 17:58, 28 November 2019
General
- Type: Low molecular weight heparin
- Dosage Forms: subcutaneous
- Common Trade Names: Lovenox
Adult Dosing
Therapeutic anticoagulation (e.g. treating DVT/PE, unstable angina)
- 1mg/kg SC q12h
Chemical Prophylaxis of VTE
- Lovenox 30mg SubQ q12 hrs (if Cr Clearance > 30)
- Check Anti-Xa level every week EXACTLY 4 hours after 3rd dose of lovenox
- prophylactic goal: 0.2-0.6
- therapeutic goal: 0.6-1.2
- Check Anti-Xa level every week EXACTLY 4 hours after 3rd dose of lovenox
- Recheck AntiXa level after each 3rd dose if dose is changed until you are at goal
- Recheck level every week (usually qMonday) for all patients
- If renal dysfunction order heparin 5000 Units SubQ q8 hrs (search “SURG DVT/VTE prophylaxis” order set)
Pediatric Dosing
Off-label
- DVT prophylaxis:
- <2 months: 0.75 mg/kg SC q12hr
- ≥2 months: 0.5 mg/kg SC q12h
- Therapeutic anticoagulation:
- <2 months: 1.5 mg/kg SC q12hr
- ≥2 months: 1 mg/kg SC q12hr
Special Populations
- Pregnancy Rating: B
- Lactation: Unknown risk
- Renal Dosing
- Renal impairment (creatinine clearance <30)
- Use 50% of usual dose or use UFH instead
- Renal impairment (creatinine clearance <30)
- Hepatic Dosing: not established
- Obesity
- Weight-based dosing safe up to 190kg (no data available thereafter)
Indications
Contraindications
- Allergy to class/drug
Adverse Reactions
- Bleeding
- Pruritus
- Local skin reaction
Pharmacology
- Half-life: 4.5h
- Metabolism: hepatic
- Excretion: urine
- Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III